Caris Life Sciences (NASDAQ:CAI) Sets New 52-Week Low – What’s Next?

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI) reached a new 52-week low during trading on Monday . The stock traded as low as $18.61 and last traded at $18.63, with a volume of 715179 shares changing hands. The stock had previously closed at $19.53.

Wall Street Analysts Forecast Growth

CAI has been the subject of several analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Evercore set a $38.00 target price on Caris Life Sciences in a research note on Monday, January 5th. Robert W. Baird started coverage on Caris Life Sciences in a research report on Tuesday, February 17th. They set an “outperform” rating and a $26.00 price target on the stock. Canaccord Genuity Group lifted their price target on Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. Finally, Wall Street Zen lowered Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Caris Life Sciences has an average rating of “Hold” and a consensus price target of $31.33.

Caris Life Sciences Price Performance

The firm has a 50 day moving average price of $25.30. The firm has a market capitalization of $4.98 billion and a P/E ratio of -38.35. The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79.

Insider Activity

In other news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the transaction, the insider directly owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. The trade was a 38.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Institutional Trading of Caris Life Sciences

Several large investors have recently added to or reduced their stakes in CAI. Global Retirement Partners LLC raised its holdings in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares in the last quarter. Olistico Wealth LLC purchased a new position in shares of Caris Life Sciences during the fourth quarter valued at about $31,000. MetLife Investment Management LLC raised its stake in Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after buying an additional 755 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Caris Life Sciences in the fourth quarter worth about $67,000. Finally, Federated Hermes Inc. purchased a new stake in Caris Life Sciences in the fourth quarter worth about $81,000.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.